Is vancomycin FDA-approved?

Yes. It has been FDA-approved since 1958 and is a standard, guideline-recommended prescription antibiotic used under medical supervision in hospitals.

Why do doctors monitor vancomycin blood levels?

Because both effectiveness and toxicity depend on drug exposure. Current guidelines recommend AUC-guided monitoring to keep exposure in a target range that maximizes efficacy against MRSA while limiting kidney injury.

What are the main side effects of vancomycin?

The most important is nephrotoxicity (acute kidney injury), which is why renal function and drug levels are monitored. Rapid infusion can cause red-man/vancomycin flushing syndrome; less common effects include ototoxicity and low blood counts.

Is vancomycin a peptide?

It is a glycopeptide antibiotic - a peptide-based natural product bearing sugar groups. It is not a research or bodybuilding peptide and has no such use; it is strictly an infection-treatment drug prescribed by clinicians.

EMA-approvedaka Vancocin

Vancomycin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Vancomycin (also known as Vancocin) is a peptide catalogued under Cyclic & Antimicrobial (Glycopeptide antibiotic). It is described as: D-Ala-D-Ala peptidoglycan. Documented context: MRSA; C. difficile. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Vancomycin?

Vancomycin is a glycopeptide antibiotic, FDA-approved since 1958, that remains a first-line intravenous agent for serious Gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, endocarditis, pneumonia, skin/soft-tissue, bone and CNS infections; oral vancomycin is used for Clostridioides difficile colitis.

It is a physician-prescribed, hospital-administered prescription drug, not a supplement or research chemical, and its use is anchored by high-quality evidence: IDSA clinical practice guidelines and multi-society therapeutic-monitoring consensus guidelines.

The evidence base is human and clinical, including randomized trials, large observational cohorts, and formal guideline consensus.

How does Vancomycin work?

Vancomycin binds the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation and thereby inhibiting bacterial cell-wall synthesis.

This mechanism is active against Gram-positive organisms but not Gram-negatives, whose outer membrane the large glycopeptide molecule cannot cross.

What does the research say about Vancomycin?

Vancomycin is a guideline-recommended first-line therapy for a range of invasive MRSA infections in adults and children. ^[2]
Efficacy and toxicity track drug exposure, so guidelines recommend AUC-guided therapeutic monitoring (target AUC/MIC around 400-600) rather than trough-only dosing for serious MRSA infections. ^[1]
Decades of clinical use establish it as a benchmark comparator against which newer anti-MRSA agents are measured. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists — Rybak MJ et al., American Journal of Health-System Pharmacy 2020. (Consensus guideline)
[2] Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children — Liu C et al., Clinical Infectious Diseases 2011. (Clinical practice guideline)
[3] Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists — Rybak M et al., American Journal of Health-System Pharmacy 2009. (Consensus review)
[4] Vancomycin: a history — Levine DP et al., Clinical Infectious Diseases 2006. (Narrative review)
[5] The Nephrotoxicity of Vancomycin — Filippone EJ et al., Clinical Pharmacology and Therapeutics 2017. (Narrative review)
[6] Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter — van Hal SJ et al., Antimicrobial Agents and Chemotherapy 2013. (Systematic review and meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: vancomycin is given intravenously in hospital, typically as a weight-based loading dose followed by maintenance dosing individualized by renal function and Bayesian/AUC-based therapeutic drug monitoring.

This is not self-administered; dosing, monitoring and adjustment are managed by clinicians and pharmacists, and nothing here is dosing advice.

Side effects & safety profile

The principal dose-related toxicity is nephrotoxicity (acute kidney injury); systematic review and meta-analysis links higher troughs and higher exposures to increased AKI risk, which is why level/AUC monitoring is standard.

Infusion-related reactions - classically red-man (vancomycin flushing) syndrome - can occur with rapid infusion and are mitigated by slower administration; ototoxicity, neutropenia and thrombocytopenia are less common.

Vancomycin must only be used under medical supervision with baseline and serial renal function and drug-level monitoring; risk rises with concurrent nephrotoxins such as aminoglycosides or piperacillin-tazobactam.

Stacking & combinations

In practice it is sometimes combined with other agents (for example beta-lactams or rifampin) only under specialist guidance, and combining it with other nephrotoxic drugs raises kidney-injury risk.

Finding Vancomycin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is an intravenous antibiotic for serious Gram-positive infections, most notably MRSA (bacteremia, endocarditis, pneumonia, bone, skin and CNS infections). Oral vancomycin is used specifically for Clostridioides difficile colitis and is not absorbed systemically.

References

[1] Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists — Rybak MJ et al., American Journal of Health-System Pharmacy 2020. PMID: 32191793. View sourceStudy: Consensus guidelineRecommends AUC-guided vancomycin dosing/monitoring (AUC/MIC 400-600) over trough-only targets for serious MRSA infections.
[2] Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children — Liu C et al., Clinical Infectious Diseases 2011. PMID: 21208910. View sourceStudy: Clinical practice guidelinePositions vancomycin as first-line therapy across multiple invasive MRSA syndromes in adults and children.
[3] Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists — Rybak M et al., American Journal of Health-System Pharmacy 2009. PMID: 19106348. View sourceStudy: Consensus reviewEarlier multi-society consensus establishing exposure targets and the rationale for vancomycin therapeutic drug monitoring.
[4] Vancomycin: a history — Levine DP et al., Clinical Infectious Diseases 2006. PMID: 16323120. View sourceStudy: Narrative reviewReviews vancomycin's discovery, chemistry and evolution into the standard anti-MRSA glycopeptide.
[5] The Nephrotoxicity of Vancomycin — Filippone EJ et al., Clinical Pharmacology and Therapeutics 2017. PMID: 28474732. View sourceStudy: Narrative reviewSummarizes mechanisms, risk factors and exposure-dependence of vancomycin-associated kidney injury.
[6] Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter — van Hal SJ et al., Antimicrobial Agents and Chemotherapy 2013. PMID: 23165462. View sourceStudy: Systematic review and meta-analysisHigher vancomycin troughs/exposure are associated with significantly increased risk of nephrotoxicity.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.